Heartsciences vs Pavmed
Pavmed is the larger business, with $71,000 of revenue in fiscal 2025 against $4,319 for Heartsciences (16.4 times as much). Heartsciences grew faster (-0.7% against -97.6%). Pavmed kept more of each dollar of sales as profit: a net margin of 564.8% against -211666.5%. Pavmed carries less debt relative to equity (23.1% against 1602.3%).
| Latest fiscal year | HeartsciencesHSCS, 2026 | PavmedPAVM, 2025 |
|---|---|---|
| Revenue | $4,319 | $71,000 |
| Revenue growth | -0.7% | -97.6% |
| Net income | −$9.1m | $401,000 |
| Operating margin | -194787.4% | -30712.7% |
| Net margin | -211666.5% | 564.8% |
| Return on equity | — | 2.5% |
| Free cash flow | −$7.4m | −$5.2m |
| Cash | $1.7m | $1.5m |
| Total debt | $3.6m | $7.8m |
| Debt to equity | 1602.3% | 23.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 14 | 41 |
| Market value | $11.6m | $11.7m |
| Price vs our value range | — | — |
| Moat score | — | 20 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |